Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Novel treatment options for Waldenström macroglobulinemia.
[waldenström macroglobulinemia]
Waldenström
macroglobulinemia
(
WM
)
,
first
described
by
Jan
Waldenström
in
1944
,
is
a
lymphoplasmacytic
lymphoma
characterized
by
the
presence
of
an
immunoglobulin
M
monoclonal
gammopathy
in
the
blood
and
monoclonal
small
lymphocytes
and
lymphoplasmacytoid
cells
in
the
bone
marrow
.
WM
is
a
rare
and
indolent
disease
but
remains
incurable
.
In
this
review
we
discuss
the
pathogenesis
of
WM
and
focus
on
novel
treatment
options
that
target
pathways
deregulated
in
this
disease
.
Recent
studies
have
helped
us
identify
specific
genetic
mutations
that
are
commonly
seen
in
WM
and
might
prove
to
be
important
therapeutic
targets
in
the
future
.
We
discuss
the
role
of
epigenetics
and
the
changes
in
the
bone
marrow
microenvironment
that
are
important
in
the
pathogenesis
of
WM
.
The
commonly
used
drugs
are
discussed
with
a
focus
on
novel
agents
that
are
currently
being
used
as
single
agents
or
in
combination
to
treat
WM
.
We
finally
focus
on
some
agents
that
have
shown
preclinical
efficacy
and
might
be
available
in
the
near
future
.
